Allworth Financial LP Has $489,000 Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Allworth Financial LP raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 607.1% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,405 shares of the biopharmaceutical company’s stock after buying an additional 8,075 shares during the quarter. Allworth Financial LP’s holdings in Halozyme Therapeutics were worth $489,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in HALO. Profund Advisors LLC boosted its position in shares of Halozyme Therapeutics by 40.2% in the second quarter. Profund Advisors LLC now owns 38,440 shares of the biopharmaceutical company’s stock valued at $2,000,000 after acquiring an additional 11,021 shares during the period. Future Fund LLC boosted its holdings in Halozyme Therapeutics by 64.7% in the 2nd quarter. Future Fund LLC now owns 55,692 shares of the biopharmaceutical company’s stock valued at $2,897,000 after purchasing an additional 21,873 shares during the period. Pier 88 Investment Partners LLC grew its position in Halozyme Therapeutics by 32.3% in the 2nd quarter. Pier 88 Investment Partners LLC now owns 10,520 shares of the biopharmaceutical company’s stock worth $547,000 after purchasing an additional 2,570 shares during the last quarter. Los Angeles Capital Management LLC grew its position in Halozyme Therapeutics by 951.8% in the 2nd quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company’s stock worth $50,650,000 after purchasing an additional 881,094 shares during the last quarter. Finally, Paradigm Asset Management Co. LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $713,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $70.03 on Monday. The firm has a market capitalization of $8.24 billion, a P/E ratio of 16.03, a P/E/G ratio of 0.35 and a beta of 1.18. The stock has a fifty day moving average price of $70.27 and a two-hundred day moving average price of $63.23. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $79.50. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.27 EPS. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HALO has been the subject of several research reports. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. Weiss Ratings reiterated a “buy (b)” rating on shares of Halozyme Therapeutics in a research report on Thursday. Leerink Partnrs upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. JMP Securities upped their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Seven investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $75.00.

Insiders Place Their Bets

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the sale, the chief executive officer directly owned 733,719 shares in the company, valued at $50,721,994.47. This represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $68.48, for a total value of $136,960.00. Following the sale, the director directly owned 42,952 shares of the company’s stock, valued at $2,941,352.96. This represents a 4.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 110,227 shares of company stock valued at $8,028,955. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.